MUCOPOLYSACCHARIDOSIS (MPS) TREATMENT MARKET ANALYSIS

Regional Analysis

Global Mucopolysaccharidosis (MPS) Treatment Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global mucopolysaccharidosis (MPS) treatment market over the forecast period. North America is estimated to hold 34.1% of the market share in 2023. The  mucopolysaccharidosis (MPS) treatment market is expected to witness significant growth, driven by the increasing focus on developing advanced products by companies. Rising product launches and approvals in the North America region are expected to boost the market growth over the forecast period. For instance, in August 2022, REGENXBIO Inc., a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, announced its plans to file a Biologics License Application (BLA) in 2024 using the U.S. FDA's accelerated approval pathway for RGX-121 for the treatment of mucopolysaccharidosis Type II (MPS II). In February 2022, Homology Medicines, Inc. is a genetic medicines company, presented data on HMI-203, a gene therapy candidate for the treatment of Hunter syndrome (MPS II), under a phase I dose-escalation clinical study in adults with Mucopolysaccharidosis, at the Annual WorldSymposium Meeting held in U.S.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa